EMA Refused: Kynamro (mipomersen sodium) — Genzyme Europe BV

View source ↗

Summary

The EMA refused approval for Kynamro (mipomersen sodium) by Genzyme Europe BV for hypercholesterolemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Kynamro (mipomersen)

Snippet

Status: Refused. Therapeutic area: Hypercholesterolemia. MAH: Genzyme Europe BV. Decision date: 14/12/2012